Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 24, 2026JAMA Oncology

Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRashidul Alam MahumudYCYifu ChenMSMd Shahjalal

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mahumud et al. (2026) studied this question.

synapsesocial.com/papers/6975661bd5e0d64addde87b2https://doi.org/10.1001/jamaoncol.2025.6080
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective2026
  2. 2Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review2025
  3. 3Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer2025
  4. 4Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses2025
  5. 5Research Progress and Safety Evaluation of Immunotherapy for Cancer2025